Novartis
NEWS
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
Specifically, the trial of Spartalizumab did not meet the primary endpoint of investigator-assessed progression-free survival.
The U.S. Food and Drug Administration (FDA) approved Novartis’ Kesimpta (ofatumumab) for relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
The legal ruling, subject to appeal, protects the Swiss pharma giant’s revenue stream from the blockbuster drug Gilenya for a little bit longer.
Novartis plans to make the drugs available to government, non-governmental organizations (NGOs) and other institutional customers in up to 79 countries at no profit.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
Novartis is the first company to the finish line with an approved treatment for Adult-Onset Still’s Disease (AOSD), a rare autoinflammatory disease of unknown origin.
On Tuesday, the FDA extended its review of the Supplemental Biologics License Application for Arzerra in this indication by three months.
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
JOBS
IN THE PRESS